Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sibutramine in weight control: a dose-ranging, efficacy study.

M Weintraub1, A Rubio, A Golik

  • 1Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, NY.

Clinical Pharmacology and Therapeutics
|September 1, 1991
PubMed
Summary

Sibutramine, at 5 and 20 mg doses, significantly enhanced weight loss when combined with lifestyle changes. This medication demonstrated a dose-dependent effect, aiding obese participants in achieving greater weight reduction over 12 weeks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress disorder cases reported by UK occupational physicians 1996-2024.

Occupational medicine (Oxford, England)·2026
Same author

Management of anastomotic leak following restorative rectal cancer resection-a multi-centre retrospective audit in Ireland.

Irish journal of medical science·2026
Same author

Imaging a terahertz superfluid plasmon in a two-dimensional superconductor.

Nature·2026
Same author

Pulmonary Vein Isolation: Patient Experience under Conscious Sedation versus Anaesthesia.

Irish medical journal·2026
Same author

Exploring the pangenome of Mycoplasma hyorhinis in search of potential virulence markers.

Scientific reports·2025
Same author

Superstability of micrometre jets surrounded by a polymeric shell.

Journal of applied crystallography·2025

Area of Science:

  • Pharmacology
  • Obesity Research
  • Clinical Trials

Background:

  • Obesity is a significant public health concern requiring effective management strategies.
  • Multimodal approaches combining pharmacotherapy with lifestyle interventions are crucial for sustainable weight loss.
  • Sibutramine is a serotonin and norepinephrine reuptake inhibitor investigated for its anti-obesity effects.

Purpose of the Study:

  • To evaluate the safety and efficacy of sibutramine (5 mg and 20 mg) as an adjunct to a multimodal weight loss program.
  • To determine the dose-response relationship of sibutramine in promoting weight loss.
  • To assess adverse events associated with sibutramine use in an overweight population.

Main Methods:

  • A parallel-group, double-blind, placebo-controlled clinical trial was conducted over 12 weeks.

Related Experiment Videos

  • Participants (130%-180% of ideal body weight) received caloric restriction, behavior modification, exercise, and either placebo, 5 mg sibutramine, or 20 mg sibutramine.
  • Weight loss and adverse events were monitored throughout the study period.

    • Main Results:

    • Significant weight loss was observed in both sibutramine groups compared to placebo (5 mg: 2.9 kg, 20 mg: 5.0 kg vs. placebo: 1.4 kg).
    • A significant dose-effect relationship was evident, with the 20 mg dose yielding greater weight loss than the 5 mg dose (p < 0.05).
    • Adverse events led to study discontinuation in five participants; sleep disturbances and irritability were more frequent in the 20 mg sibutramine group.

    Conclusions:

    • Sibutramine, at both 5 mg and 20 mg doses, effectively enhances weight loss when integrated into a comprehensive lifestyle modification program.
    • The 20 mg dose demonstrated a superior effect on weight reduction compared to the 5 mg dose.
    • While effective, potential adverse effects such as sleep difficulties and irritability warrant careful consideration and monitoring during sibutramine therapy.